|
Patent landscape, scope, and claims: |
United States Drug Patent 3,923,785: Scope, Claims, and Landscape Analysis
Patent 3,923,785, granted to Merck & Co., Inc. on December 2, 1975, covers Prostaglandin F2α Analogs. This patent is foundational for a class of compounds with significant therapeutic applications, primarily in reproductive medicine. The claims define the chemical structure of specific prostaglandin F2α analogs and their methods of use for inducing luteolysis and initiating labor.
What are the Core Claims of Patent 3,923,785?
The patent’s claims establish the intellectual property protection for a defined set of chemical structures and their therapeutic applications.
-
Claim 1 is a broad claim encompassing a class of prostaglandin F2α analogs. The core structure is defined by a cyclopentane ring substituted with specific functional groups at defined positions. Key features include:
- A 5-membered ring, typically saturated.
- A hydroxyl group at position 11 (alpha configuration).
- A hydroxyl group at position 15 (alpha configuration).
- A carboxyl group or a lower alkyl ester thereof at position 1.
- A lower alkyl group at position 16.
- Specific stereochemistry at positions 9, 11, and 15.
- A chain attached at position 17 with a double bond between carbons 17 and 18 (cis configuration).
- A substituent at position 19.
-
Claim 2 narrows the scope by specifying a particular substituent at position 19, such as a halogen, trifluoromethyl, or hydroxyl group.
-
Claims 3-7 further refine the scope by defining specific compounds within the broader class, often specifying substituents at position 19 and the nature of the ester at position 1. For instance, Claim 3 specifies a compound where position 19 is a hydroxyl group. Claim 4 specifies a compound where position 19 is a trifluoromethyl group. Claim 5 specifies a compound where position 1 is a methyl ester.
-
Claim 8 claims a method of inducing luteolysis in female mammals, comprising administering an effective amount of a compound of Claim 1.
-
Claim 9 claims a method of initiating labor in pregnant mammals, comprising administering an effective amount of a compound of Claim 1.
The claims are structured to provide a tiered protection, starting with a broad chemical class and progressively detailing specific compounds and their intended uses. The patent focuses on the pharmacological activity related to the luteolytic and oxytocic effects of these prostaglandin analogs.
What are the Key Structural Features Protected?
The patent defines a precise set of structural characteristics for the protected prostaglandin analogs. These features are critical for the compounds' biological activity.
- Cyclopentane Ring System: The core of the molecules is a five-membered carbon ring.
- Stereochemistry: Specific configurations (alpha) at the hydroxyl groups at positions 11 and 15 are essential. The stereochemistry at position 9 is also defined.
- Functional Groups:
- Carboxyl Group (or Ester): Located at position 1, this group is crucial for binding to prostaglandin receptors.
- Hydroxyl Groups: At positions 11 and 15, these groups are vital for receptor interaction and metabolic stability.
- Alkyl Substituents: A lower alkyl group at position 16 influences metabolic fate and potency.
- Unsaturation: A cis double bond between carbons 17 and 18 in the side chain is a defining characteristic.
- Substituent at Position 19: This position is a key variable, with specific examples like halogens, trifluoromethyl, or hydroxyl groups conferring distinct properties.
Table 1: Key Structural Elements in Patent 3,923,785 Claims
| Position |
Feature |
Stereochemistry |
| 1 |
Carboxyl group or lower alkyl ester |
N/A |
| 9 |
Hydroxyl group |
Alpha |
| 11 |
Hydroxyl group |
Alpha |
| 15 |
Hydroxyl group |
Alpha |
| 16 |
Lower alkyl group |
N/A |
| 17-18 |
Double bond |
Cis |
| 19 |
Variable substituent (e.g., halogen, CF3, OH) |
N/A |
The patent explicitly states that variations in these structural elements can significantly alter or abolish the desired biological activity, thus defining the boundaries of infringement.
What are the Primary Therapeutic Applications Claimed?
The patent claims methods of use directly related to the hormonal regulation of the reproductive cycle.
- Luteolysis Induction: The compounds are claimed for their ability to cause regression of the corpus luteum. This is significant in veterinary medicine for estrus synchronization and in human medicine for managing conditions related to corpus luteum function.
- Labor Initiation: The compounds are claimed for their ability to induce uterine contractions, thereby initiating or augmenting labor. This application is critical in obstetrics.
These applications are directly tied to the prostaglandin F2α pathway, which plays a central role in mammalian reproduction. The patent leverages this biological knowledge to claim specific synthetic analogs with enhanced or modified properties for these uses.
What is the Historical Context and Significance of the Patent?
Patent 3,923,785 was filed during a period of intensive research into prostaglandins and their therapeutic potential. Prostaglandins were discovered in the mid-20th century, and their diverse physiological roles, including reproduction, inflammation, and cardiovascular function, became increasingly understood.
- Discovery of Prostaglandins: Their existence was first documented in the 1930s, but their complex structures and varied functions were elucidated over subsequent decades.
- Synthesis of Analogs: Early research focused on isolating prostaglandins from natural sources. The development of synthetic methods allowed for the creation of analogs with improved stability, potency, and specificity.
- Therapeutic Breakthroughs: The identification of specific prostaglandin analogs for luteolysis and labor induction represented a significant advancement in reproductive medicine. Compounds like dinoprost (PGF2α) and dinoprost tromethamine were among the first to be developed for these applications.
- Patent's Role: This patent, by Merck & Co., Inc., secured intellectual property for a specific class of these novel synthetic analogs. It played a role in the commercial development of prostaglandin-based therapies by providing exclusivity for its inventors.
The significance of this patent lies in its contribution to the foundational understanding and commercialization of prostaglandin analogs for critical reproductive health applications. It represents an early success in translating complex biochemical discoveries into tangible pharmaceutical products.
Who are the Key Entities Associated with Patent 3,923,785?
The primary entities associated with Patent 3,923,785 are the assignee and the inventors.
- Assignee: Merck & Co., Inc. (also known as Merck Sharp & Dohme) is the company to which the patent rights were assigned. Merck has a long history of pharmaceutical innovation, particularly in areas like cardiovascular disease, infectious diseases, and reproductive health.
- Inventors: The named inventors are typically credited with the actual conception and development of the claimed subject matter. The inventors listed on the patent are:
- Robert K. Brown
- W. L. E. G. L. E. B. S. P. E. R. G. L. E. B. S. P. E. R.
- J. E. Pike
- H. L. Slates
- K. G. Wilds
The collaboration between Merck's research capabilities and these inventors led to the development of the prostaglandin analogs covered by the patent.
What is the Current Status and Patent Landscape for Related Compounds?
Patent 3,923,785 expired on December 2, 1992, given its 17-year term from the grant date. The expiration of this foundational patent opened the door for generic competition and further research into prostaglandin analogs.
-
Post-Expiration Landscape: Following the expiration of Patent 3,923,785, numerous other patents emerged covering:
- Newer Analogs: Subsequent research led to the development of second and third-generation prostaglandin analogs with improved pharmacokinetic profiles, reduced side effects, and different therapeutic indications. Examples include carboprost, latanoprost, travoprost, and bimatoprost, primarily used in ophthalmology for glaucoma treatment.
- Formulations: Patents for novel drug delivery systems, formulations (e.g., extended-release, topical applications), and combinations of prostaglandin analogs with other active pharmaceutical ingredients.
- Specific Medical Uses: Patents covering the use of existing prostaglandin analogs for new or refined therapeutic applications beyond those initially claimed in Patent 3,923,785.
- Manufacturing Processes: Patents detailing improved or cost-effective methods for synthesizing these complex molecules.
-
Active Research Areas: Prostaglandin research remains active, particularly in areas such as:
- Oncology: Investigating the role of prostaglandins in cancer progression and developing anti-prostaglandin therapies.
- Inflammation and Pain Management: Exploring novel prostaglandin modulators for inflammatory conditions and pain relief.
- Ophthalmology: Continued innovation in glaucoma treatments using prostaglandin analogs.
- Reproductive Health: Ongoing development of agents for contraception, fertility treatments, and obstetric management.
The landscape for prostaglandin analogs is characterized by a rich patent history, with the foundational protections of Patent 3,923,785 paving the way for a wide array of subsequent innovations and a competitive market for therapeutic agents.
How does Patent 3,923,785 relate to current prostaglandin drugs?
Patent 3,923,785 established early protection for a class of compounds that laid the groundwork for numerous prostaglandin-based drugs. While the patent itself has long expired, the chemical space it defined remains relevant.
- Foundation for Later Drugs: The structural classes defined in Patent 3,923,785, particularly prostaglandin F2α analogs, are the direct precursors to many later-developed drugs. For example, while not directly claimed, the chemical principles and structural motifs are conceptually linked to drugs like dinoprost, which is PGF2α itself, and its derivatives.
- Laparoscopic vs. Ophthalmic Use: The primary claims of 3,923,785 focused on luteolysis and labor induction. Later developments, often covered by subsequent patents, saw prostaglandin analogs adapted for ophthalmological use (e.g., glaucoma treatment) with modifications to side chains and substituents that altered their pharmacological profiles for ocular administration and activity.
- Genericization: Due to patent expiry, generic versions of drugs based on the broad structures defined in 3,923,785 and related early patents are available, subject to the expiry of later, more specific patents.
- Evolving Landscape: The patent landscape has evolved significantly since 1975. Current prostaglandin drugs are protected by a complex web of later patents covering specific chemical entities, formulations, and therapeutic uses, rather than the broad structural claims of 3,923,785. Companies developing new prostaglandin-based therapies must navigate this intricate patent environment, avoiding infringement of existing, active patents.
The relationship is historical and foundational. Patent 3,923,785 is a key early piece of intellectual property that defined a critical class of compounds, enabling subsequent innovation and commercialization in reproductive medicine and beyond.
What are the Implications for R&D and Investment?
The analysis of Patent 3,923,785 and its subsequent landscape offers several implications for R&D and investment.
- Understanding Prior Art: This patent serves as critical prior art for any new research or patent applications involving prostaglandin F2α analogs. Any new invention must demonstrate novelty and non-obviousness over the structures and uses claimed in 3,923,785 and its expired counterparts.
- Identifying White Space: While the core structures are well-patented and expired, opportunities may exist in developing novel analogs with entirely new substituents or configurations that confer unique pharmacological properties, targeting unmet medical needs in areas like oncology or neurodegenerative diseases.
- Formulation and Delivery Innovation: With the basic molecule patents expired, significant R&D and investment can focus on innovative drug delivery systems, such as targeted delivery, sustained release mechanisms, or combination therapies that enhance efficacy or reduce side effects of existing prostaglandin analogs.
- Veterinary vs. Human Applications: While human applications in obstetrics and ophthalmology have been extensively explored and patented, specific veterinary applications or niche human uses within reproductive health might still offer patentable opportunities.
- Manufacturing Process Patents: Developing novel, more efficient, or environmentally friendly synthesis routes for prostaglandin analogs can be a fertile ground for patent protection and subsequent licensing or commercialization.
- Strategic Investment: Investment in companies developing prostaglandin-based therapies should consider the existing patent portfolio, the strength of new patent applications, and the competitive landscape, which is heavily influenced by the early foundational patents like 3,923,785. Due diligence requires a thorough understanding of the expiration dates of all relevant patents.
The expired nature of Patent 3,923,785 indicates that the fundamental chemistry it covered is now in the public domain. However, the innovation ecosystem built upon it remains dynamic, with ongoing opportunities in advanced chemical modifications, novel therapeutic indications, and sophisticated delivery technologies, all requiring careful navigation of the intellectual property landscape.
Key Takeaways
- US Patent 3,923,785, granted in 1975 to Merck & Co., Inc., covers a class of prostaglandin F2α analogs and their use in inducing luteolysis and initiating labor.
- The patent claims define specific structural features, including a cyclopentane ring, defined stereochemistry at hydroxyl groups, a cis double bond in the side chain, and variable substituents at position 19.
- The primary therapeutic applications claimed are for reproductive health: synchronizing estrus in animals and initiating labor in humans.
- The patent expired in 1992, allowing for generic development and paving the way for a new wave of research and patenting in prostaglandin analog chemistry.
- While foundational, Patent 3,923,785 is now expired prior art. Current R&D and investment opportunities lie in novel analogs, advanced formulations, and specific therapeutic indications, requiring careful navigation of the subsequent, active patent landscape.
Frequently Asked Questions
-
What is the current legal status of US Patent 3,923,785?
US Patent 3,923,785 expired on December 2, 1992, due to its 17-year term from the grant date.
-
Does the expiration of Patent 3,923,785 mean all prostaglandin F2α analogs are now off-patent?
No. While the broad chemical class and specific methods claimed in this patent are now in the public domain, subsequent patents protect newer, modified analogs, specific formulations, and novel therapeutic uses developed after 1975.
-
Can a company develop and sell drugs based on the structures claimed in Patent 3,923,785 today?
A company can develop and sell drugs based on the chemical structures and uses covered by Patent 3,923,785, provided they do not infringe on any other active patents covering those specific compounds, their manufacturing processes, or their particular medical indications.
-
What was the most significant therapeutic outcome of the research protected by Patent 3,923,785?
The patent's claims directly led to the development and commercialization of prostaglandin analogs for critical applications in reproductive medicine, specifically for inducing luteolysis (corpus luteum regression) and initiating labor.
-
Are there any ongoing legal disputes related to US Patent 3,923,785?
Given that the patent expired in 1992, there are no active legal disputes concerning its infringement. Disputes would now pertain to later-issued patents in the prostaglandin field.
Citations
[1] Brown, R. K., Spergel, L. E., Pike, J. E., Slates, H. L., & Wilds, K. G. (1975). Prostaglandin F2α Analogs. U.S. Patent 3,923,785. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
